 The 21-hydroxylated derivative of this compound, tetrahydrodeoxycorticosterone (THDOC), is an endogenous inhibitory neurosteroid with similar properties to those of allopregnanolone, and the 3β-methyl analogue of allopregnanolone, ganaxolone, is under development to treat epilepsy and other conditions, including post-traumatic stress disorder (PTSD).In March 2019, brexanolone was approved in the United States for the treatment of postpartum depression (PPD) in adult women.Brexanolone is the first drug approved by the U.S. Food and Drug Administration (FDA) specifically for PPD.